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Summary
 
Human natural killer (NK) cells express several killer cell immunoglobulin (Ig)-like receptors
(KIRs) that inhibit their cytotoxicity upon recognition of human histocompatibility leukocyte
antigen (HLA) class I molecules on target cells. Additional members of the KIR family, includ-
ing some that deliver activation signals, have unknown ligand specificity and function. One
such KIR, denoted KIR2DL4, is structurally divergent from other KIRs in the configuration
of its two extracellular Ig domains and of its transmembrane and cytoplasmic domains. Here we
show that recombinant soluble KIR2DL4 binds to cells expressing HLA-G but not to cells ex-
pressing other HLA class I molecules. Unlike other HLA class I–specific KIRs, which are
clonally distributed on NK cells, KIR2DL4 is expressed at the surface of all NK cells. Further-
more, functional transfer of KIR2DL4 into the cell line NK-92 resulted in inhibition of lysis of
target cells that express HLA-G, but not target cells that express other class I molecules includ-
ing HLA-E. Therefore, given that HLA-G expression is restricted to fetal trophoblast cells,
KIR2DL4 may provide important signals to maternal NK decidual cells that interact with tro-
phoblast cells at the maternal–fetal interface during pregnancy.
Key words: natural killer cell • human histocompatibility leukocyte antigen G • killer cell 
immunoglobulin-like receptor • pregnancy • trophoblast
 
H
 
uman NK cells express two types of receptors that
bind to HLA class I molecules on target cells (1). The
killer cell Ig-like receptors (KIRs)
 
1
 
 form a family including
members that inhibit NK cells upon recognition of specific
classical HLA class I molecules, in particular HLA-C and
HLA-B. In addition, the lectin-like CD94/NKG2A het-
erodimer is an inhibitory receptor specific for the nonclas-
sical class I molecule HLA-E (2–4). Another nonclassical
HLA class I molecule, HLA-G, has been reported to in-
hibit NK cells (5–8). However, the protection of HLA-
G–expressing target cells from NK-mediated lysis can be ex-
plained by the recognition of HLA-E on these cells by the
CD94/NKG2A receptor. Cell surface expression of HLA-E
depends on the binding of a specific peptide derived from
the leader sequence of other class I molecules, including
HLA-G (9, 10).
The KIR and NKG2 families include members that acti-
vate, rather than inhibit, NK cells (1, 11). These activating
receptors, such as KIR2DS and NKG2C, have short cyto-
plasmic tails that lack immunoreceptor tyrosine-based inhi-
bition motifs (ITIMs). In addition, a lysine residue in their
transmembrane domain contributes to their association
with DAP12 (12), a homodimer of a 12-kD molecule with
a cytoplasmic immunoreceptor tyrosine-based activation
motif (ITAM). In contrast, the inhibitory receptors, such as
KIR2DL, KIR3DL, and NKG2A, have long cytoplasmic
tails with two ITIM sequences. In their case, inhibition is
achieved by the recruitment of the tyrosine phosphatase
SHP-1 to phosphorylated ITIMs. Expression of the differ-
ent KIR and NKG2 family members, including activating
and inhibitory forms, is clonally distributed among NK
cells. Individual NK cells express several such receptors at
once, in no particular combination. Besides the few inhibi-
tory KIRs with established specificities for HLA class I, all
other KIR family members have poorly defined ligand
specificities.
HLA-G is expressed only on fetal trophoblast cells that in-
vade the maternal decidua (13). These invading trophoblast
cells are surrounded by maternal stromal cells and NK cells
that are abundant in the decidua basalis during early preg-
nancy. It has been proposed that HLA-G on trophoblast cells
interacts with a receptor on NK cells (13). Such an interac-
tion may serve to inhibit NK cytotoxicity, but may also pro-
vide signals that result in a positive NK response.
 
1
 
Abbreviations used in this paper:
 
 ITAM, immunoreceptor tyrosine-based
activation motif; ITIM, immunoreceptor tyrosine-based inhibition motif;
KIR, killer cell immunoglobulin-like receptor. 
1094
 
HLA-G–specific NK Receptor
 
In a search for an HLA-G–specific receptor, soluble
forms of several KIRs were produced and tested for bind-
ing to transfected cells expressing HLA-G. One of the
KIRs of unknown function, called KIR2DL4, is structur-
ally unique among the KIR family members. Complemen-
tary DNA clones encoding KIR2DL4 predict a molecule
with two Ig domains in a unique D0–D2 configuration
(14, 15). Other KIRs have either two or three Ig domains
in the order D1–D2 or D0–D1–D2, respectively. The pre-
dicted transmembrane region that includes an arginine resi-
due and the long cytoplasmic tail with a single ITIM are
also unique. Therefore, KIR2DL4 has features typical of
both activating and inhibitory receptors, leaving some un-
certainty as to what type of signal it may deliver to NK
cells. In this study, we describe expression of KIR2DL4 at
the surface of all NK cells and identify it as an HLA-G–spe-
cific receptor.
 
Materials and Methods
 
Cells and Antibodies.
 
The NK cell lines NK3.3 (a gift from J.
Kornbluth, St. Louis University School of Medicine, St. Louis,
MO) and NK-92 (obtained from H.-G. Klingemann, Rush Uni-
versity, Chicago, IL) were cultured as previously described (16,
17). HLA class I transfectants of the 721.221 cell line were ob-
tained from J. Gumperz and P. Parham (Stanford University,
Stanford, CA), except for the HLA-G transfectant, which was
obtained from L. Lanier (DNAX, Palo Alto, CA). The T leuke-
mic cell line Jurkat and the monocytic cell line HL60 were ob-
tained from the American Type Culture Collection. RMA-S
cells transfected with HLA-E (RMA-S-E) cells were obtained
from E.H. Weiss and M. Ulbrecht (Institut für Anthropologie
and Humangenetik der Universität München, Munich, Ger-
many) and used as previously described (3). NK clones were pro-
duced from the peripheral blood of normal donors as previously
described (18). Anti-CD3 and anti-CD56 antibodies conjugated
 
to PE were purchased from Becton Dickinson. The HLA-spe-
cific mAb B9.12.1, the KIR2DL1-reactive mAb EB6, and iso-
type-matched control Abs were obtained from Immunotech.
Rabbit antisera to the NH
 
2
 
-terminal region of KIR2DL4 (re-
ferred to as anti-2DL4) were raised by immunization with the
synthetic peptide VGGQDLPFC, and were affinity purified on
the same peptide (Research Genetics). The mAb VV1-IG10, spe-
cific for the A33 early/intermediate vaccinia protein, was a gift of
A. Schmaljohn (U.S. Army, Fort Detrick, Frederick, MD). The
MHC class I–specific mAb DX17 was a gift of L. Lanier. The
HLA-G–specific mAb (G233) was a gift of A. King (Cambridge
University, Cambridge, UK). This mAb does not react with clas-
sical HLA molecules and reacts with HLA-G in extravillous tro-
phoblasts (19).
 
KIR2DL4–Ig Fusion Proteins and Binding Assay.
 
The KIR2DL4–
Ig fusion protein was produced by the same strategy used for other
KIR–Ig proteins (20). The extracellular region was PCR amplified
from a cDNA clone of KIR2DL4 obtained from A. Selvakumar
and B. Dupont (Memorial Sloan Kettering Cancer Center, New
York, NY) with the forward primer CAGAGTGTGCTAGCG-
CACGTGGGTGGTCAGGACAAGCC containing an NheI site,
and the reverse primer GAGTACCTAGGATCCGCATGCAG-
GTGTCTGGCGATACC containing a BamHI site. These PCR
fragments were cloned into the expression vector Cd5lneg1 (ob-
tained from B. Seed, Massachusetts General Hospital, Charles-
town, MA). SDS-PAGE analysis of the purified recombinant
protein identified a species of 
 
z
 
65 kD under reducing condi-
tions. The binding assay was performed as previously described
(20), except that the cells were incubated with goat IgG (50 
 
m
 
g/ml)
for 30 min after incubation with the 2DL4–Ig fusion protein and
before addition of the FITC-conjugated goat anti–human Fc.
Binding was assessed by flow cytometry.
 
Vaccinia Virus Infection, Cytotoxicity Assays, and Peptide Loading.
 
cDNAs encoding KIR2DL4 and NKG2A (obtained from J.
Houchins, R&D Systems, Minneapolis, MN) were subcloned
into the plasmid pSC65 and used to generate recombinant vac-
cinia viruses as previously described (21). Purified viruses encod-
ing KIR2DL4 or NKG2A were used to infect the human cell
Figure 1. Binding of soluble
KIR2DL4–Ig to 221–G cells. (A)
721.221 (221) and 721.221 trans-
fectants expressing HLA-Cw*0304
(221-Cw3) or HLA-G (221-G)
were incubated with no fusion
protein, 25 mg/ml of 2DL2–Ig, or
25 mg/ml of 2DL4–Ig. The bound
fusion proteins were detected by
flow cytometry after reaction
with  FITC-conjugated goat anti–
human Fc specific antibodies. Data
are expressed as median fluores-
cence intensity (MFI). Inset, histo-
gram profile (filled) of ungated
221-G cells stained with 2DL4–Ig.
Open histogram is control staining
with secondary antibodies alone.
(B) Binding of KIR2DL4–Ig to
721.221 transfectants was detected
as described in A. Cell surface ex-
pression of HLA class I on the dif-
ferent cells, as detected by staining
with the mAb DX17, was as fol-
lows (MFI in parenthesis): 221
(21); 221–B7 (1,731); 221–Cw3
(588); and 221–G (1,540). 
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line NK-92, as previously described (20). Vaccinia virus infec-
tions were monitored by flow cytometry with the mAb VV1-
IG10. Infected and uninfected control cells were simultaneously
plated for standard 
 
51
 
Cr-release assays and for Ab staining fol-
lowed by flow cytometry as previously described (20). Peptide
loading was done as previously described (3). In brief, 500 
 
m
 
M of
the HLA-G signal sequence peptide (VMAPRTFL) was incu-
bated overnight with RMA-S-E cells plated at 5 
 
3
 
 10
 
5
 
 cells/ml.
Cells were washed and used for antibody staining followed by
flow cytometry.
 
Results and Discussion
 
Direct Binding of Soluble KIR2DL4 to 721.221 Cells Ex-
pressing HLA-G.
 
A soluble recombinant protein contain-
ing the extracellular portion of KIR2DL4 fused to the Fc
region of human IgG1 (KIR2DL4–Ig) was produced in or-
der to search for its ligand. Binding of KIR2DL4–Ig to a
panel of HLA-transfected 721.221 cells was analyzed by
flow cytometry. KIR2DL4–Ig displayed a uniform binding
to all the 721.221 transfectants tested, as well as untrans-
fected 721.221 cells (Fig. 1 A). This HLA class I–indepen-
dent binding of KIR2DL4 to 721.221 cells may be due to
the first Ig domain (D0), as similar results have been re-
ported with soluble KIR3DL1 (22) and KIR3DL2 (23),
both of which contain a D0 domain, and with a soluble
D0–Ig fusion protein (22). In contrast, KIR2DL4–Ig
bound strongly to 721.221 cells expressing HLA-G (221–G).
As expected, KIR2DL2–Ig bound to its ligand HLA-Cw3
but not to HLA-G expressed on 721.221 cells (Fig. 1 A).
Unlike previous studies describing weak and heterogeneous
binding of the similar p49 KIR (15) and the Ig-like transcript
(ILT)-2 and ILT-4 members of the ILT inhibitory receptor
family expressed mainly on monocytic cells (24, 25), binding
of KIR2DL4–Ig to HLA-G was detected by flow cytometry
as a bright and uniform peak (Fig. 1 A, inset).
The panel of HLA transfectants included HLA-A1, -A2,
-B7, -Cw3 and -G, all permissive for HLA-E expression,
and HLA-B46, -B51, and -B58, which are not permissive
for HLA-E expression (Fig. 1, and data not shown). Thus,
it is unlikely that the KIR2DL4–Ig binds to the HLA-E
molecules that reach the cell surface upon binding the pep-
tide derived from the HLA-G leader sequence. The com-
parison of KIR2DL4–Ig binding to 221–B7 and 221–G
cells (Fig. 1 B) provides further evidence that KIR2DL4 is
not binding to HLA-E. The peptide from the HLA-B7
leader sequence binds HLA-E fivefold better than the
HLA-G–derived leader peptide in an in vitro peptide bind-
ing assay, resulting in higher HLA-E surface expression (2).
Yet despite a very high surface level of HLA-B7 expression
on 221–B7 cells, there was no binding of KIR2DL4–Ig to
221–B7 above the HLA-independent binding (Fig. 1 B).
 
Cell Surface Expression of KIR2DL4 on All NK Cells.
 
The KIR2DL4 gene is transcribed in every NK cell tested
(15, 26), but there is no information on protein expression of
KIR2DL4 in NK cells. An antiserum against a peptide corre-
sponding to a unique NH
 
2
 
-terminal sequence of KIR2DL4
was produced to examine cell surface expression of KIR2DL4
on a panel of NK, T, B, and monocyte/macrophage cell
lines. The anti-KIR2DL4 (anti-2DL4) antiserum reacted
with the NK cell lines NK-92 and NK3.3. (Fig. 2 A). There
was negligible staining of cell lines such as the T leukemic
line Jurkat, the B cell line 721.221, and the monocytic cell
Figure 2. Cell surface expression of KIR2DL4 on NK cells. (A) Flow
cytometry profiles of the T leukemia cell line Jurkat, the B lymphoblas-
toid cell line 721.221, the monocytic cell line HL60 and the NK cell lines
NK-92 and NK3.3 as well as a CD32CD561CD942 NK clone. Cells
were incubated with anti-2DL4 antiserum followed by FITC anti–rabbit
IgG. (B) Flow cytometry analysis of CD32CD561 NK cells isolated from
the peripheral blood of a normal donor and double stained with PE-con-
jugated CD56 and rabbit anti-2DL4 antiserum followed by FITC-conju-
gated goat anti–rabbit IgG. The percentages of total cells in each quadrant
are listed. (C) Flow cytometry analysis of a primary T cell culture from a
normal donor gated on CD31 cells and double stained for PE-conjugated
CD3 and rabbit anti-2DL4 followed by FITC-conjugated goat anti–rab-
bit IgG. The percentages of total cells in each quadrant are listed. 
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line HL-60. All NK clones in a random panel tested (
 
n
 
 
 
5
 
14) expressed uniformly high cell surface KIR2DL4 (Fig.
2 A). To test whether KIR2DL4 was expressed on all
NK cells, CD3
 
2
 
CD56
 
1
 
 cells were isolated from the periph-
eral blood lymphocytes of four donors. All CD56
 
1
 
 cells
(
 
.
 
99%) in these cultures reacted with the anti-2DL4 anti-
serum (Fig. 2 B). In contrast, only 2% of the CD3
 
1
 
 lym-
phocytes reacted with the anti-2DL4 antiserum (Fig. 2 B).
The proportion of KIR2DL4
 
1
 
 cells within the CD3
 
1
 
 pop-
ulation varied between 1 and 9% among six donors tested.
Three-color analysis of the CD3
 
1
 
2DL4
 
1
 
 subpopulation by
flow cytometry showed that the majority of these cells also
expressed the NK marker CD56 (data not shown).
 
Functional Transfer of KIR2DL4 in NK-92 Cells.
 
A re-
combinant vaccinia virus encoding KIR2DL4 (vac-2DL4)
was produced for functional transfer experiments in order
to confirm the ligand specificity seen in binding studies and
to test whether KIR2DL4 can inhibit the lysis of HLA-G–
bearing targets. The highly lytic NK tumor cell line NK-92,
chosen because it has been used successfully for vaccinia vi-
rus-mediated expression (18, 20), was tested for the inhibi-
tion of lysis of 721.221 target cells expressing different
HLA class I molecules. NK-92 cells express a low endoge-
nous level of KIR2DL4 as determined by flow cytometry
(Figs. 2 A and 3 A). In multiple experiments (
 
n
 
 
 
5
 
 30), lysis
of the HLA-G–expressing target cell 221–G was reduced to
73 
 
6
 
 19% of the lysis observed with the HLA class I–defi-
cient parental cell 721.221. This low but reproducible inhibi-
tion would be consistent with recognition of HLA-G by en-
dogenous KIR2DL4. The level of expression of KIR2DL4
on infected NK-92 (Fig. 3 A) was very similar to that of
endogenous KIR2DL4 on NK clones (Fig. 2 A). Vaccinia
virus–infected NK-92 cells expressing KIR2DL4 lysed
721.221 cells and 721.221 cells transfected with HLA-Cw4
(Fig. 3 B). In contrast, there was striking inhibition of lysis of
221–G cells. A number of other 721.221 transfectants ex-
pressing HLA class I genes, such as HLA-A1, -A2, -B7,
-B58, -Cw3, and -Cw7, were not protected from lysis by
NK-92 cells expressing KIR2DL4 (Table I, and data not
shown). If 221–G cells are protected from lysis through rec-
ognition of HLA-G by KIR2DL4, lysis should be restored in
the presence of anti–HLA class I antibodies such as DX17
(27). KIR2DL4-expressing NK-92 cells incubated with tar-
get cells in the presence of DX17 mAb lysed the 221–G cells
to the same extent as untransfected 721.221 cells (Fig. 3 C).
Several HLA class I molecules, including HLA-G, are
permissive for the expression of HLA-E (2–4). However,
lysis of the HLA-E–permissive 221–Cw4 cells by NK cells
expressing KIR2DL4 (Fig. 2) suggests that HLA-E is not
recognized by KIR2DL4. To further distinguish between
HLA-G– and HLA-E–mediated protection, NK-92 cells
expressing either KIR2DL4 or the HLA-E–specific inhibi-
tory receptor CD94/NKG2A were tested against a panel of
721.221 cells transfected with individual HLA class I genes.
The endogenous CD94/NKG2A present on NK-92 cells is
not sufficient to provide inhibition of lysis upon recogni-
tion of HLA-E–expressing target cells (Table I). However,
increasing the cell surface expression of NKG2A using a re-
combinant vaccinia virus (as detected by flow cytometry;
data not shown) resulted in inhibition of lysis that corre-
lated with HLA-E expression (Table I). Thus, there was in-
hibition of lysis of target cells expressing HLA-A1, -Cw3,
-Cw4, and -G, but not HLA-B58, an allele not permissive
for HLA-E expression (Table I). It is worth noting that the
complete inhibition of 221–G target cell lysis by NK-92 in-
fected with vac-NKG2A may reflect the combined inhibi-
Figure 3. Functional transfer of KIR2DL4 in NK-92 cells results in HLA-G–mediated inhibition. (A) Flow cytometry analysis of cell surface
KIR2DL4 in NK-92 cells either uninfected, or infected with vac-2DL4 (15 PFU/cell). The cells were stained with either anti-2DL4 rabbit antiserum
followed by FITC goat anti–rabbit IgG or with the mAb VV1-1G10 specific for a vaccinia cell surface protein. The histograms show log fluorescence of
ungated cells. (B) Aliquots of uninfected or vac-2DL4–infected cells in A were tested for their ability to lyse 721.221 cells and 721.221 cells transfected
with HLA-Cw*0401 and HLA-G, in a 4-h 51Cr-release assay. Lysis is shown for an E/T ratio of 5. Similar data was obtained at other E/T ratios and in
five independent experiments. (C) Aliquots of NK-92 cells infected with vac-2DL4 were tested for their ability to lyse 721.221 (squares) or 221-G cells
(triangles) in the presence of 5 mg/ml of the anti-class I mAb DX17 (open symbols) or control IgG1 (filled symbols). Similar results were obtained in two
independent experiments. 
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tion mediated by recognition of HLA-E by CD94/NKG2A
and of HLA-G by endogenous KIR2DL4. In contrast, as re-
ported above, NK-92 cells expressing KIR2DL4 were in-
hibited only by HLA-G–expressing cells and not by cells ex-
pressing other HLA class I molecules along with HLA-E.
These data show that functional transfer of KIR2DL4 into
NK-92 cells conferred specificity for HLA-G, leading to in-
hibition of target cell lysis.
Finally, to obtain independent evidence that HLA-G and
not HLA-E is recognized by KIR2DL4, we tested the ef-
fect of an HLA-G–specific mAb on the KIR2DL4-medi-
ated inhibition of NK-92. To test whether this mAb may
recognize HLA-E in the context of a bound peptide derived
from the HLA-G signal peptide, the transporter for antigen
presentation (TAP)-deficient mouse RMA-S cell trans-
fected with HLA-E (denoted RMAS-E) was loaded with
the HLA-G signal sequence peptide VMAPRTLFL at 26
 
8
 
C.
This resulted in increased surface stabilization of HLA-E as
detected with the anti-HLA mAb B9.12.1. However, no
binding of mAb G233 was detected (Fig. 4 A). Thus, mAb
G233 does not recognize HLA-E. NK-92 cells were infected
with recombinant vaccinia viruses encoding KIR2DL1 or
KIR2DL4, resulting in high surface expression of these re-
ceptors (Fig. 4 B). Lysis of 221–G target cells was tested in
the presence of G233 mAb or an isotype-matched IgG2a.
Only G233 restored the lysis of 221–G cells by KIR2DL4-
expressing NK-92 cells to the level observed with KIR2DL1-
expressing NK-92 (Fig. 4 C). mAb G233 had no effect on
the inhibition of lysis of 221–Cw4 cells by KIR2DL1-
expressing NK-92 cells (data not shown).
These data demonstrate that the single ITIM in the con-
text of the KIR2DL4 molecule can deliver an inhibitory
 
Table I. 
 
Inhibition of Lysis of 721.221 Cells by NK92 Cells Expressing NKG2A and KIR2DL4
 
Transfected
HLA class I
Surface
level of
class I
 
*
 
Permissive
for surface
HLA-E
 
‡
 
Percentage of specific lysis
 
§
 
Uninfected vac–2DL4 vac–NKG2A
None 10
 
2
 
101 103 102
A
 
*
 
0101 125
 
1
 
98 88
 
45
 
B
 
*
 
5801 322
 
2
 
100 103 100
Cw
 
*
 
0304 155
 
1
 
86 83
 
41
 
Cw
 
*
 
0401 114
 
1
 
87 85
 
28
 
G 259
 
1
 
62
 
21 0
 
*
 
Cell surface MHC class I expression is expressed as median fluorescence intensity (MFI) and was assessed using the anti–class I mAb W6/32.
 
‡
 
See reference 2.
 
§
 
Lysis of 721.221 transfectants was detected using a 
 
51
 
Cr-release assay and data is shown at an E/T ratio of 8. Similar results were obtained in three
independent experiments.
Figure 4. KIR2DL4-mediated recognition of HLA-G is reversed using a HLA-G–specific mAb that does not recognize HLA-E. (A) mAb G233 does
not recognize HLA-E. RMAS-E cells were loaded with 500 mM of the HLA-G signal sequence–derived peptide VMAPRTLFL at 268C and stained
with either the anti-HLA reactive mAb B9.12.1 or the HLA-G specific mAb G233. The staining of 221-G cells using both antibodies is shown in the
bottom panel. (B) Flow cytometry analysis of cell surface KIR2DL1 and KIR2DL4 in NK-92 cells infected with either vac-2DL1 or vac-2DL4. Cells
were stained with mAb EB6 (specific for KIR2DL1), mAb VV1-1G10 (anti-vac), or anti-2DL4 rabbit antiserum followed by FITC-labeled species-spe-
cific secondary reagents. (C) Aliquots of infected cells expressing KIR2DL1 or KIR2DL4 were tested for their ability to lyse 221-Cw3, 221-Cw4, or
221-G target cells. The interaction between vac-2DL4 expressing NK-92 cells and those expressing 221-G was tested in the presence of either 5 mg/ml
of isotype-matched control IgG2a (cIg) or HLA-G–specific mAb G233. Similar results were obtained in three independent experiments. 
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signal in NK-92 cells. Experiments to test the possibility
that KIR2DL4 may interact with other proteins via the
positively charged arginine residue in the transmembrane
domain have been hampered by the lack of an anti-
KIR2DL4 antibody suitable for immunoprecipitations. It is
possible that the inhibitory activity of KIR2DL4, clearly
evident in the cell line NK-92, could be modulated in
other cells by association with ITAM-bearing molecules
such as DAP12 (which associates with KIR2DS, CD94/
NKG2C, and Ly49D/H; references 12, 28, 29) or FcR
 
g
 
(which associates with ILT-1 and NKR-P1; references 30,
31). In this regard, it is interesting that the cell line NK3.3
and some NK clones are not inhibited by HLA-G despite
expression of KIR2DL4 (6, 8, 32, and our unpublished ob-
servations).
In conclusion, these results clearly identify KIR2DL4 as
a specific receptor for HLA-G, by both direct binding and
functional transfer. Previously, the only NK receptor that
reproducibly inhibited the lysis of HLA-G–expressing cells
by NK cells was the CD94/NKG2A heterodimer (6–8).
However, this inhibition can be explained by the binding
of CD94/NKG2A to the class Ib molecule HLA-E. More-
over, CD94/NKG2A is not expressed by all NK cells (26,
33), and CD94
 
2
 
 NK cells that are inhibited by HLA-G
have been reported (6–8), suggesting the existence of yet
another NK receptor specific for HLA-G. The ILT2 re-
ceptor expressed on monocytes and on a subset of NK cells
can also inhibit lysis of target cells expressing HLA-G (34).
However, in contrast to KIR2DL4, ILT2 and CD94/
NKG2A are not expressed by all NK cells.
The basis for the immune privilege of the fetus, which is
a hemi-allogeneic graft, represents an interesting immuno-
logical puzzle. Trophoblast cells do not express HLA-A or
HLA-B molecules on their cell surface, a feature thought to
confer protection from T cell responses. In contrast, ex-
pression of HLA-G on trophoblast cells may result in a func-
tional interaction with KIR2DL4 on maternal decidual NK
cells. CD16
 
2
 
CD56
 
bright
 
 NK cells constitute the major pop-
ulation of lymphocytes in the decidua (13). The outcome
of this interaction in situ remains to be established and
might involve the regulation of a number of NK functions
such as cytotoxicity, cytokine production, or proliferation.
For example, the high expression of HLA-G on cytotro-
phoblasts may play a role in preventing local activation of
maternal NK cells. This may provide a basis for earlier ob-
servations showing that cultured fetal trophoblast cells are
resistant to lysis by NK cells isolated from either human de-
cidua or peripheral blood (35). Alternatively, recognition
of HLA-G by KIR2DL4-expressing NK cells might regu-
late trophoblast differentiation or invasion into the mater-
nal decidua. Delineating the biological significance of the
HLA-G–KIR2DL4 interaction at the maternal–fetal inter-
face will be a step towards resolving the apparent immuno-
logical paradox of a successful pregnancy.
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